Imprime PGG Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at

Share Article adds “Imprime PGG (Colorectal Cancer) – Forecast and Market Analysis to 2023” to its store. This report focuses on the current treatment landscape, unmet needs, current pipeline and commercial opportunities in the colorectal cancer market.

Imprime PGG Colorectal Cancer Treatment Market

Imprime PGG Colorectal Cancer Treatment Market

The report “Imprime PGG (Colorectal Cancer) – Forecast and Market Analysis to 2023” focuses on the current treatment landscape, unmet needs, current pipeline and commercial opportunities in the colorectal cancer market. Biothera’s Imprime PGG is an immunotherapy in Phase III development in the US and Europe for the treatment of chemotherapy-refractory KRAS wild-type metastatic CRC in combination with the EGFR inhibitor Erbitux. Its open-label pivotal study has an estimated enrollment of 795 patients, and these patients will be randomized (2:1) to either Imprime PGG and Erbitux or Erbitux alone. The trial has a primary endpoint of OS, with final data for this outcome expected in April 2016; the company is investigating the potential to apply for accelerated approval based on interim data when available. Complete Report is Available @ .

Prescribe for the treatment of colorectal cancer Imprime PGG, the drug targets immune system cells (neutrophils and monocytes). The drug is mimics the natural innate immune response against pathogens and redirects it to kill antibody-targeted cancer cells. As imprime PGG is not specific for a certain cancer, it can be used for treating different types of cancer lymphocytic leukemia and lung cancer. As the drug triggers immune cells without inducing pro-inflammatory cytokines, it therefore reduces side effects.

Reasons to Buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Imprime PGG performance
  • Obtain sales forecast for Imprime PGG from 2013-2023 in top six countries (the US, France, Germany, Italy, Spain and the UK)

Order a Purchase copy of report @ .

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports

3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Clinical Staging
3.3 Symptoms

4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Screening and Diagnosis
4.1.2 Treatment Guidelines and Leading Prescribed Drugs
4.1.3 Clinical Practice

5 Competitive Assessment
5.1 Overview

6 Unmet Need and Opportunity
6.1 Overview
6.2 Therapies That Provide Substantial Overall Survival Benefit for Metastatic Patients
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Targeted Treatments for KRAS and BRAF Mutaton-Positive Patients
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Tolerable Later-Line Therapies For Chemotherapy-Resistant Patients
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity

7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development

8 Imprime PGG
8.1 Overview
8.2 Efficacy
8.3 Safety
8.4 Dosing and Formulation
8.5 Potential Clinical and Commercial Positioning
8.6 SWOT Analysis
8.7 Forecast

9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed Colorectal Cancer Patients
9.4.2 Percent Drug-Treated Patients
9.4.3 General Pricing Assumptions
9.4.4 Average Body Weight and Surface Area Across the 8MM
9.4.5 Generic Erosion
9.4.6 Pricing of Pipeline Agents
9.5 Primary Research - KOLs Interviewed for this Report
9.6 Primary Research - Prescriber Survey
9.7 About the Authors
9.7.1 Analyst
9.7.2 Global Head of Healthcare
9.8 About GlobalData
9.9 Disclaimer

List of Tables
Table 1: TNM and Staging Classification System for CRC
Table 2: Symptoms of Colorectal Cancer
Table 3: Treatment Guidelines for CRC
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013
Table 6: Leading Treatments for CRC, 2014
Table 7: Unmet Need and Opportunity in CRC
Table 8: Product Profile - Imprime PGG
Table 9: Imprime PGG SWOT Analysis, 2014
Table 10: Global Sales Forecasts ($m) for Imprime PGG, 2013-2023
Table 11: Average Body Weight and Surface Area Across the 8MM
Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: CRC - Phase III Pipeline
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in CRC, 2013-2023
Figure 3: Clinical and Commercial Positioning of Imprime PGG

Explore more reports on Cancer Drugs industry at .

About Us: is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
Follow >
Sandler Research
since: 04/2014
Like >
Follow us on
Visit website